In vitro- and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 829-835

  Holle, Lori ^a   Song, Wen ^a   Holle, Eric ^a   Wei, Yangzhang ^a,b   Li, Jinhua ^a   Wagner, Thomas E ^a,b   Yu, Xianzhong ^a,b  

^a Greenville Hospital System Oncology Research Institute   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Cancer; Fusion protein; Latency associated peptide; Lytic peptides; Matrix metalloproteinase 2; Melittin

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; LATENCY ASSOCIATED PEPTIDE MATRIX METALLOPROTEINASE 2 MELITTIN FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG TARGETING; FEMALE; FUSION GENE; GENE AMPLIFICATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION; TUMOR VOLUME; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE THERAPY; GENETIC VECTORS; LATENT TGF-BETA BINDING PROTEINS; MATRIX METALLOPROTEINASE 2; MELANOMA, EXPERIMENTAL; MELITTEN; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 70449393157     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000396     Document Type: Article

References (27)

1. Mach N and Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12: 571-575, 2000.
2. Rossowska J and Pajtasz-Piasecka E: Dendritic cells and their applications in cancer immunotherapy - achievements and future prospects. Postepy Hig Med Dosw 57: 501-518, 2003.
3. Desai SB and Libutti SK: Tumor angiogenesis and endothelial cell modulatory factors. J Immunother 22: 186-211, 1997.
4. Brower V: Tumor angiogenesis - new drugs on the block. Nat Biotechnol 17: 963-968, 1999.
5. Perry PJ, Gowan SM, Read MA, Kelland LR and Neidle S: Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif. Anticancer Drug Des 14: 373-382, 1999.
6. Fridman WH and Tartour E: The use of cytokines in the treatment of solid tumours. Hematol Cell Ther 39: 105-108, 1997. (Pubitemid 27309274)
7. Trail PA and Bianchi A: Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 11: 584-588, 1999. (Pubitemid 29462136)
8. Denny WA: Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Invest 22: 604-619, 2004. (Pubitemid 39506881)
9. Chari RVJ: Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 31: 89-104, 1998.
10. Sinhababu AK and Thakker DR: Prodrugs of anticancer agents. Adv Drug Deliv Rev 19: 241-273, 1996.
11. Kingsley DM: The TGF-ß superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8: 133-146, 1994. (Pubitemid 2044355)
12. Taipale J, Koli K and Keski-Oja J: Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 267: 25378-25384, 1992.
13. Adams G, Vessillier S, Dreja H and Chernajovsky Y: Targeting cytokines to inflammation sites. Nat Biotechnol 21: 1314-1320, 2003.
14. Nissim A, Gofur Y, Vessillier S, Adams G and Chernajovsky Y: Methods for targeting biologicals to specific disease sites. Trends Mol Med 10: 269-274, 2004. (Pubitemid 38725894)
15. Leuschner C and Hansel W: Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 10: 2299-2310, 2004. (Pubitemid 38855038)
16. Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH and Frankel AE: A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther 5: 2556-2562, 2006. (Pubitemid 44650920)
17. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT and Denmeade SR: A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99: 376-385, 2007. (Pubitemid 47073481)
18. Panchal RG, Cusack E, Cheley S and Bayley H: Tumor protease-activated, pore-forming toxins from a combinatorial library. Nat Biotechnol 14: 852-856, 1996. (Pubitemid 26239183)
19. Hansel W, Leuschner C and Enright F: Conjugates of lytic peptides and LHRH of ßCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 269: 26-33, 2007. (Pubitemid 46483829)
20. Holle L, Song W., Holle E, Wei Y, Wagner T and Yu X: A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 22: 93-98, 2003.
21. Ling CZ, Li B, Zhang C, Zhu DZ, Huang XQ, Gu W and Li SX: Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma. Ann Oncol 16: 109-115, 2005. (Pubitemid 40124487)
22. Werkmeister JA, Kirkpatrick A, McKenzie JA and Rivett DE: The effect of sequence variations and structure on the cytolytic activity of melittin peptides. Biochim Biophys Acta 1157: 50-54, 1993. (Pubitemid 23138469)
23. Barrett-Lee P, Travers M, Luqmani Y and Coombes RC: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61: 612-617, 1990. (Pubitemid 20126345)
24. Coffey RJ Jr, Shipley GD and Moses HL: Production of transforming growth factors by human colon cancer lines. Cancer Res 46: 1164-1169, 1986. (Pubitemid 16048249)
25. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, et al: Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635, 1995. (Pubitemid 3018923)
26. Bottinger EP, Factor VM, Tsnag ML, Weatherbee JA, Kopp JB, Qian SW, et al: The recombinant proregion of transforming growth factor beta 1 (latency-associated peptide) inhibits active transforming growth factor beta 1 in transgenic mice. Proc Natl Acad Sci USA 93: 5877-5882, 1996. (Pubitemid 26190771)
27. Nagase H and Woessner JF: Matrix Metalloproteinases. J Biol Chem 274: 21491-21494, 1999.